In last trading session, ProKidney Corp (NASDAQ:PROK) saw 0.48 million shares changing hands with its beta currently measuring 1.55. Company’s recent per share price level of $0.98 trading at $0.03 or 3.24% at ring of the bell on the day assigns it a market valuation of $286.93M. That closing price of PROK’s stock is at a discount of -353.06% from its 52-week high price of $4.44 and is indicating a premium of 4.08% from its 52-week low price of $0.94. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.77 million shares which gives us an average trading volume of 499.87K if we extend that period to 3-months.
For ProKidney Corp (PROK), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2.00. Splitting up the data highlights that, out of 6 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 5 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.15 in the current quarter.
ProKidney Corp (NASDAQ:PROK) trade information
Upright in the green during last session for gaining 3.24%, in the last five days PROK remained trading in the red while hitting it’s week-highest on Friday, 03/14/25 when the stock touched $0.98 price level, adding 8.41% to its value on the day. ProKidney Corp’s shares saw a change of -41.80% in year-to-date performance and have moved -6.32% in past 5-day. ProKidney Corp (NASDAQ:PROK) showed a performance of -36.13% in past 30-days. Number of shares sold short was 11.93 million shares which calculate 32.91 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 5 to the stock, which implies a rise of 80.4% to its current value. Analysts have been projecting 3 as a low price target for the stock while placing it at a high target of 6. It follows that stock’s current price would drop -206.12% in reaching the projected high whereas dropping to the targeted low would mean a loss of -206.12% for stock’s current value.
ProKidney Corp (PROK) estimates and forecasts
In 2025, company’s earnings growth rate is likely to be around -2.23% while estimates for its earnings growth in next 5 years are of -4.91%.
ProKidney Corp (NASDAQ:PROK)’s Major holders
Insiders are in possession of 27.50% of company’s total shares while institution are holding 44.68 percent of that, with stock having share float percentage of 61.63%. Investors also watch the number of corporate investors in a company very closely, which is 44.68% institutions for ProKidney Corp that are currently holding shares of the company.
On the other hand, Vanguard Total Stock Market Index Fund and Morgan Stanley Inst Fd Inc-Growth Port are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 2.97 shares of worth $2.92 million or 2.32% of the total outstanding shares. The later fund manager was in possession of 2.92 shares on Dec 31, 2024 , making its stake of worth around $2.88 million in the company or a holder of 2.28% of company’s stock.
